Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.80 USD
Change Today +0.0015 / 0.19%
Volume 39.6K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/13/14 - $1.43
52 Week Low
05/15/15 - $0.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DARA BIOSCIENCES INC (DARA)

Related News

No related news articles were found.

dara biosciences inc (DARA) Related Businessweek News

No Related Businessweek News Found

dara biosciences inc (DARA) Details

DARA BioSciences, Inc., a specialty pharmaceutical company, focuses on commercialization of oncology treatment and supportive care pharmaceutical products in the United States. The company’s products comprise Soltamox, an oral solution for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups; Gelclair, an oral gel for the treatment of oral mucositis; Bionect for the management of irritation of the skin, as well as first and second degree burns; Ferralet 90 for treatment of anemia; and Aquoral for treatment of cancer. Its clinical development products include KRN5500, a novel, non-narcotic/non-opioid intravenous product for the treatment of cancer patients with painful chronic chemotherapy induced peripheral neuropathy, which has completed Phase 2a development. The company was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

15 Employees
Last Reported Date: 03/3/15
Founded in 2002

dara biosciences inc (DARA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $464.4K
Executive Chairman and Chief Medical Officer
Total Annual Compensation: $487.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

dara biosciences inc (DARA) Key Developments

Midatech Pharma Plc, DARA BioSciences, Inc - M&A Call

To discuss the Midatech Pharma Plc's proposed acquisition of DARA BioSciences, Inc.

NASDAQ Grants Additional 180-Day Period To DARA BioSciences To Regain Compliance

On May 19, 2015, DARA BioSciences, Inc, received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market (NASDAQ) indicating that the NASDAQ Listing Qualifications Staff has granted the company's request for an additional 180-day period in which to regain compliance with the minimum $1.00 bid price per share requirement. The NASDAQ Listing Qualifications Staff's determination to grant the additional 180 day compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the additional 180-day compliance period by effecting a reverse stock split, if necessary.

DARA BioSciences, Inc Reports Earnings Results for the First Quarter Ended March 31, 2015

DARA BioSciences Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of $652,200 for the first quarter ended March 31, 2015 based on gross product sales in excess of $850,000, as compared to net revenues of $161,500 for the first quarter ended March 31, 2014, a year over year increase of 304%. The increase in Revenue was primarily attributable to the expanded commercial sales organization and success in generating interest and prescriptions across DARA's portfolio. Loss attributable to controlling interest of approximately $3.2 million or $0.16 per share for the first quarter ended March 31, 2015 as compared to a loss attributable to controlling interest of approximately $2.7 million, or $0.37 per share for the first quarter ended March 31, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $0.80 USD +0.0015

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $6.89 USD +0.325
View Industry Companies

Industry Analysis


Industry Average

Valuation DARA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at